The role of P53 in the early detection of sarcoma
David Thomas, PhD, FRACP, The Kinghorn Cancer Centre, Sydney, Australia, discusses how whole genome sequencing can be utilized to identify p53 mutations that drive the progression of silent sarcomas at early disease stages. Prof. Thomas emphasizes the significance of whole-body MRI in detecting these silent malignancies at a curable stage, whilst also highlighting the prospect of potential blood-based detection strategies to enhance detection and intervention in those at risk. This interview took place at the 2023 ESMO annual Sarcoma and Rare Cancers congress in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Suggested videos

Immunotherapy updates in head and neck cancer from ASCO 2026
VJOncology · 18:35

The Tumor Suppressor p53 and the Ultimate Model System: Man
RCMI Program UPR Medical Sciences Campus · 1:24:27

Phase I trial of ICV-delivered bivalent CAR T-cells in glioblastoma
VJOncology · 2:46

Dr. Landen Discusses p53 Mutations in Ovarian Cancer
OncLive · 1:40

What is the future role of ctDNA as a biomarker in colorectal cancer?
VJOncology · 2:07

Using Circulating Tumor DNA to Monitor Sarcoma Treatment and Recurrence
Stanford Surgery · 8:05

iwCAR-T 2026: advances in TIL therapy for solid tumors
VJOncology · 19:20

Significance of p53 mutations in AML
VJHemOnc – Video Journal of Hematology & HemOnc · 1:03

Safety and efficacy outcomes of SMART-based SABR in ultracentral NSCLC
VJOncology · 1:23

Oncogenetics - Mechanism of Cancer (tumor suppressor genes and oncogenes)
Armando Hasudungan · 11:24

Reprogramming the tumor microenvironment: targeting acidity to unlock antitumor immunity
VJOncology · 11:53

Diagnosis of Pediatric Osteogenic Sarcoma
Alexandros G. Sfakianakis · 2:50